Cytokinetics | CYTK - Operating Profit

Stock Price
66.27
Daily Change
-3.83 -5.46%
Monthly
4.87%
Yearly
41.42%
Q1 Forecast
65.83

Cytokinetics reported $-178.37M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Arca Biopharma USD -25.09M 5.23M Mar/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
Brainstorm Cell Therapeutics USD -3.09M 100K Mar/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Capricor Therapeutics USD -24.98M 17.28M Mar/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Geron USD -13.89M 1.43M Sep/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025